Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Not yet recruiting 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 220Rectal Neoplasms 137Stomach Neoplasms 95Colonic Neoplasms 87Pancreatic Neoplasms 82Esophageal Neoplasms 71Neoplasm Metastasis 58Squamous Cell Carcinoma of Head and Neck 43Head and Neck Neoplasms 42Adenocarcinoma Of Esophagus 37Neoplasms 36Breast Neoplasms 35Esophageal Squamous Cell Carcinoma 27Carcinoma, Hepatocellular 22Cholangiocarcinoma 21Adenocarcinoma 17Nasopharyngeal Carcinoma 16Bile Duct Neoplasms 14Gallbladder Neoplasms 13Carcinoma, Squamous Cell 13Biliary Tract Neoplasms 13Anus Neoplasms 13Urinary Bladder Neoplasms 11Liver Neoplasms 10Carcinoma 9Nasopharyngeal Neoplasms 8Colorectal Cancer Metastatic 8Peritoneal Neoplasms 7Recurrence 6Ovarian Neoplasms 6

Interventions

lenvatinib 3Fluorouracil 3Drug Therapy 3Oxaliplatin 2Leucovorin 2Gemcitabine 2Folfox protocol 2Floxuridine 2regorafenib 1gemcitabine-oxaliplatin regimen 1durvalumab 1donafenib 1apatinib 1Surgical Procedures, Operative 1Radiotherapy 1Dexamethasone 1Cryosurgery 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Cirrhosis, Familial, with Pulmonary Hypertension × Fluorouracil × Clear all
NCT06739252 2026-01-28

Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA

Peking University

Phase 2 Terminated
1 enrolled
Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma, Klatskin Tumor

NCT07353827 2026-01-20

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

Sun Yat-sen University

Phase 2 Not yet recruiting
36 enrolled
Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT06648525 2024-10-18

Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC

Harbin Medical University

Phase 2 Not yet recruiting
68 enrolled
Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡